Several other equities research analysts have also commented on ARNA. ValuEngine upgraded shares of Arena Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, December 3rd. Wood & Company reiterated a sell rating on shares of Arena Pharmaceuticals in a research note on Thursday, November 14th. Zacks Investment Research lowered shares of Arena Pharmaceuticals from a hold rating to a sell rating and set a $49.00 price objective for the company. in a research note on Monday, December 30th. JPMorgan Chase & Co. upgraded shares of Arena Pharmaceuticals from a neutral rating to an overweight rating and set a $58.00 price objective for the company in a research note on Friday, January 31st. Finally, Royal Bank of Canada reiterated a buy rating and issued a $83.00 price objective on shares of Arena Pharmaceuticals in a research note on Monday, January 27th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus target price of $63.33.
NASDAQ ARNA traded up $0.18 during trading hours on Tuesday, hitting $54.00. The company’s stock had a trading volume of 30,942 shares, compared to its average volume of 529,190. The company has a current ratio of 21.90, a quick ratio of 21.90 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $2.68 billion, a PE ratio of 5.02 and a beta of 1.64. Arena Pharmaceuticals has a 52 week low of $42.48 and a 52 week high of $64.48. The company’s 50-day simple moving average is $46.74 and its two-hundred day simple moving average is $49.42.
Arena Pharmaceuticals Company Profile
Arena Pharmaceuticals, Inc, a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include ralinepag (APD811), which is in Phase III trial to treat pulmonary arterial hypertension; etrasimod (APD334) for ulcerative colitis, and Crohn's disease, as well as for atopic dermatitis and other indications; and Olorinab (APD371), which is in Phase II trial for the treatment of gastrointestinal pain.
Further Reading: What does a neutral rating on stocks mean?
Receive News & Ratings for Arena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.